Improving selective targeting to cancer-associated fibroblasts by modifying liposomes with arginine based materials. (2nd January 2022)

• Record Type: Journal Article
• Authors: Rehman, Tanzeel Ur; Bratlie, Kaitlin M.
• Is Part Of: Journal of drug targeting. Volume 30:Number 1(2022)
• Page Start: 94
• Page End: 107
• Publication Date: 2022-01-02
• Subjects: Liposomes -- targeted drug delivery -- bioconjugation -- cancer-associated fibroblasts -- arginine -- selective targeting -- IC50; Drug delivery systems -- Periodicals; Drug Delivery Systems; Vehicles; Drug Administration Routes; Drug Evaluation; 615.7
• DOI: 10.1080/1061186X.2021.1941059
• Languages: English
• ISSNs: 1061-186X

Abstract

Abstract: A library of arginine-like surface modifiers was tested to improve the targetability of DOPE:DOPC liposomes towards myofibroblasts in a tumour microenvironment. Liposomes were characterised using zeta potential and dynamic light scattering. Cell viability remained unchanged for all liposomes. Liposomes were encapsulated using doxorubicin (DOX) with an encapsulation efficiency >94%. The toxicity of DOX-loaded liposomes was calculated via half-maximal inhibitory concentration (IC50 ) for fibroblasts and myofibroblasts. These liposomes resulted in significantly lower IC50 -values for myofibroblasts compared to fibroblasts, making them more toxic towards the myofibroblasts. Furthermore, a significant increase in cell internalisation was observed for myofibroblasts compared to fibroblasts, using fluorescein-loaded liposomes. Most importantly, a novel regression model was constructed to predict the IC50 -values for different modifications using their physicochemical properties. Fourteen modifications (A–N) were used to train and validate this model; subsequently, this regression model predicted IC50 -values for three new modifications (O, P and Q) for both fibroblasts and myofibroblasts. Predicted and measured IC50 -values showed no significant difference for fibroblasts. For myofibroblasts, modification O showed no significant difference. This study demonstrates that the tested surface modifications can improve targeting to myofibroblasts in the presence of fibroblasts and hence are suitable drug delivery vehicles for myofibroblasts in a tumour microenvironment.